Brokerages Set Cartesian Therapeutics, Inc. (NASDAQ:RNAC) PT at $42.50
Cartesian Therapeutics, Inc. (NASDAQ:RNAC – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the eight analysts that are currently covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average twelve-month price objective among analysts […]
Cartesian Therapeutics, Inc. (NASDAQ:RNAC – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the eight analysts that are currently covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average twelve-month price objective among analysts […]
